JP2005507236A - 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法 - Google Patents

抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法 Download PDF

Info

Publication number
JP2005507236A
JP2005507236A JP2002579989A JP2002579989A JP2005507236A JP 2005507236 A JP2005507236 A JP 2005507236A JP 2002579989 A JP2002579989 A JP 2002579989A JP 2002579989 A JP2002579989 A JP 2002579989A JP 2005507236 A JP2005507236 A JP 2005507236A
Authority
JP
Japan
Prior art keywords
novx
nucleic acid
protein
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002579989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507236A5 (enExample
Inventor
ムラリダラ・パディガル
スレシュ・ジー・シェノイ
ラメシュ・ケクダ
ルカ・ラステッリ
ピーター・エス・メゼス
グレンダ・スミスソン
グオ・シャオジャ・（サシャ）
バレリー・ガーラッチ
ステイシー・ジェイ・キャスマン
フェレンツ・エル・ボルドグ
リ・リ
ブライアン・ディ・ザーフーゼン
ベリザル・トゥ・チェルネフ
エシャ・エイ・ガンゴリ
コリーヌ・ア・エム・ヴェルネ
キンバリー・エイ・スピテック
ウリエル・マルヤンカル
メーラ・パトゥラジャン
チャールズ・ミラー
レイモンド・ジェイ・トーピアー・ジュニア
メルビン・ピー・ハイズ
ジンファン・ジュ
ジョン・エイ・ペイマン
エリナ・カッテルトン
ジョン・アール・マクドゥゴール
シュロミット・エディンガー
デイビッド・ジェイ・ストーン
アン・マザー
Original Assignee
キュラジェン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/114,153 external-priority patent/US20030185815A1/en
Application filed by キュラジェン コーポレイション filed Critical キュラジェン コーポレイション
Publication of JP2005507236A publication Critical patent/JP2005507236A/ja
Publication of JP2005507236A5 publication Critical patent/JP2005507236A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/0115—N-Acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (2.4.1.150)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2002579989A 2001-04-03 2002-04-03 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法 Pending JP2005507236A (ja)

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
US28108601P 2001-04-03 2001-04-03
US28190601P 2001-04-05 2001-04-05
US28202001P 2001-04-06 2001-04-06
US28293001P 2001-04-10 2001-04-10
US28351201P 2001-04-12 2001-04-12
US28344401P 2001-04-12 2001-04-12
US28371001P 2001-04-13 2001-04-13
US28365701P 2001-04-13 2001-04-13
US28367801P 2001-04-13 2001-04-13
US28423401P 2001-04-17 2001-04-17
US28532501P 2001-04-19 2001-04-19
US28538101P 2001-04-20 2001-04-20
US28606801P 2001-04-24 2001-04-24
US28629201P 2001-04-25 2001-04-25
US29669201P 2001-06-07 2001-06-07
US30088301P 2001-06-26 2001-06-26
US31100301P 2001-08-08 2001-08-08
US31197301P 2001-08-13 2001-08-13
US31290101P 2001-08-16 2001-08-16
US32228301P 2001-09-14 2001-09-14
US32744801P 2001-10-05 2001-10-05
US34573401P 2001-12-31 2001-12-31
US34575502P 2002-01-03 2002-01-03
US35439102P 2002-02-04 2002-02-04
US10/114,153 US20030185815A1 (en) 2001-04-03 2002-04-02 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
PCT/US2002/010366 WO2002081625A2 (en) 2001-04-03 2002-04-03 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use

Publications (2)

Publication Number Publication Date
JP2005507236A true JP2005507236A (ja) 2005-03-17
JP2005507236A5 JP2005507236A5 (enExample) 2006-01-05

Family

ID=28795516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002579989A Pending JP2005507236A (ja) 2001-04-03 2002-04-03 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法

Country Status (3)

Country Link
EP (1) EP1390057A4 (enExample)
JP (1) JP2005507236A (enExample)
CA (1) CA2442739A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056833A1 (en) * 2006-11-10 2008-05-15 Livtech Inc. ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
US8017118B2 (en) 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956385A1 (en) * 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
JP2003531611A (ja) * 2000-05-02 2003-10-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ナトリウム−カリウム交換体タンパク質

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056833A1 (en) * 2006-11-10 2008-05-15 Livtech Inc. ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
US8227578B2 (en) 2006-11-10 2012-07-24 Abe, Ikubo & Katayama Anti-human dlk-1 antibody showing anti-tumor activity in vivo
JP5219827B2 (ja) * 2006-11-10 2013-06-26 株式会社リブテック ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
CN103073641B (zh) * 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
US8017118B2 (en) 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo

Also Published As

Publication number Publication date
EP1390057A2 (en) 2004-02-25
CA2442739A1 (en) 2002-10-17
EP1390057A4 (en) 2005-10-12

Similar Documents

Publication Publication Date Title
JP2005518185A (ja) 新規タンパク質およびそれをコード化する核酸
JP2005512515A (ja) 治療ポリペプチド、同一物をコード化する核酸、および使用方法
US7034132B2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030185815A1 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
JP2005528080A (ja) 治療ポリペプチド、同一物をコード化する核酸、および使用方法
US20040014058A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
JP2006516082A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
EP1401858A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2005519629A (ja) 治療ポリペプチドとコード化核酸と使用方法
JP2005522186A (ja) 新規タンパク質およびそれらをコード化する核酸
JP2006501813A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
JP2005506054A (ja) 抗原性治療的ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法
US20030236188A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
JP2005518193A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
JP2004533235A (ja) 治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法
WO2002081629A2 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
JP2005506833A (ja) 抗原性ポリペプチドに結合する新規抗体、抗原をコード化する核酸、および使用方法
US20060211031A1 (en) Novel proteins and nucleic acids encoding same
EP1390057A2 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use
US20040029790A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
JP2005528886A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
JP2006507793A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
WO2002098900A2 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
JP2005508604A (ja) 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法
US20060210559A1 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090113